GALT
Galectin
--
--(--)
Market Open: --
--
--(--)
Post-Market: --
GALT Profile
Galectin Therapeutics Inc.
The leading developer of therapeutics that target galectin proteins
Biological Technology
Invalid Date
03/23/2012
NASDAQ Stock Exchange
15
12-31
Common stock
4960 Peachtree Industrial Blvd.
, Suite 240
, Norcross
, GA 30071
--
Galectin Therapeutics Inc., established in July 2000 as Pro Pharma, is a development-stage company engaged in drug development to create new therapies for cancer and fibrotic diseases. Glaxti's drug candidate is based on an approach targeting the galactoagglutinin protein, a key mediator of biological and pathological functions. Glaxti uses naturally occurring, readily available plant materials as raw materials to create proprietary complex carbohydrates with specific molecular weights and pharmaceutical properties during the production process.